Clinical outcomes of patients with hematological malignancies have been improved by current hematology treatment options. Also, many new or old anticancer drugs affect the cardiovascular system, causing heart problems like left ventricular failure, cardiovascular breakdown, blood vessel hypertension, myocardial ischemia, cardiovascular musicality problems and QTc prolongation on electrocardiograms. It is essential to become familiar with all aspects of cardiotoxicity and to immediately give these patients the proper consideration because these misunderstandings could jeopardize the substantially improved outcomes of current anticancer treatments. In a similar vein, new and established medications contribute to both primary and secondary prevention of cardiovascular infections. Patients with hematologic malignancies undergoing anticancer medication treatment or hematopoietic immature microorganism transplantation are the focus of this audit, which examines the clinical signs, preventative measures and drug the board of cardiotoxicity.
HTML PDFShare this article
Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report
